I schemia-reperfusion injury is strongly associated with increased oxidative stress, mitochondrial dysfunction, and cell death. These processes are diminished in an animal model of ischemia-reperfusion by the genetic loss or pharmacological inhibition of troponin I-interacting kinase.
During the past 3 decades, we have seen significant advances in our ability to reestablish perfusion after myocardial infarction, which has resulted in improvements in cardiac function and mortality. However, reperfusion itself can induce cell death in the area at risk called ischemia-reperfusion injury. 1 This type of injury is thought to develop when cardiomyocytes, injured by ischemia, are killed by rapid normalization of pH, calcium overload, cellular swelling, or oxidative stress. Oxidative stress, in particular reactive oxygenation species production, is thought to induce calcium handling abnormalities, protein oxidation, lipid peroxidation, and cell death. 2 The mitigation of cellular death from oxidative stress from ischemia-reperfusion injury is the focus of a recent article by Vagnozzi et al. 3 Their work investigates the novel role of the cardiac-specific protein, troponin I-interacting kinase (TNNI3K), in the development of this injury and provides an approach for treating ischemia-perfusion injury in a clinical setting. In mice, genetic overexpression of TNNI3K increased infarct size and cellular death after ischemic injury in comparison with wild-type animals or animals overexpressing kinase inactive versions of TNNI3K. The observed increase in infarct size was associated with increased reactive oxygen species production in the TNNI3K-overexpressing mice. Using an in vitro model of ischemic injury, the authors show that the overexpression of TNNI3K resulted in increased reactive oxygen species generation, altered mitochondrial membrane potentials, and diminished mitochondrial calcium flux. Mitogen-activated protein kinase (MAPK) p38 phosphorylation was enhanced in TNNI3K-overexpressing cells and was associated with increased cell death, which was blocked by pharmacological inhibitors of p38. Because TNNI3K gain of function resulted in increased infarct size and myocyte energetic abnormalities, the authors tested whether TNNI3K loss of function was protective in ischemia-reperfusion injury. To accomplish this, inducible TNNI3K knockout mice were generated and tested in an ischemia-reperfusion model. TNNI3K knockout mice developed smaller infarcts and diminished biomarker elevations 24 hours after ischemic injury in comparison with TNNI3K-competent mice. TNNI3K knockout did not improve cardiac function, dimensions, or the development of hypertrophy after permanent left coronary artery occlusion. Next, to test whether TNNI3K inhibition would be a viable therapeutic target, the authors developed chemical inhibitors of TNNI3K and tested these in an in vivo ischemia-reperfusion injury model. Mice pretreated with these compounds developed a 10% reduction in infarct size, which was associated with diminished cellular death and p38 phosphorylation. Importantly, treatment with TNNI3K inhibitors resulted in a partial improvement in cardiac function, dimensions, biomarker release, and fibrosis development 4 weeks after ischemia-reperfusion injury. Collectively, these data show that TNNI3K loss of function is protective and that pharmacological inhibition of this kinase diminishes infarct size and improves cardiac function after ischemic injury. These protective effects are associated with diminished p38 activation and reactive active oxygen species generation, as well as improved mitochondrial function.
The presented work brings several insights into the function of TNNI3K in mammalian cardiac function. Although these data are exciting, there remain unanswered questions about the function of this kinase. Although the activation of p38 MAPK has been shown previously to be deleterious, 4 the mechanism by which TNNI3K activates p38 MAPK remains unclear. In addition, the authors show the subcellular localization of TNNI3K to be located in a perinuclear distribution and not in sarcomere. These data are in contrast with prior work showing that TNNI3K localizes to the sarcomere Z disc 5 and also conflicts with a recent study suggesting that troponin I may indeed be a substrate of TNNI3K. 6 These data do, however, add to a growing literature investigating the relevance of TNNI3K in cardiac function. This cardiac-specific kinase was first identified nearly a decade ago in a yeast2-hybrid screen for proteins that interact with cardiac troponin I. 7 Subsequent studies have suggested that TNNI3K is a tyrosine kinase that belongs to the MAPK kinase kinase family, which bears structural homology to integrin-link kinase. 7 Because its reported interaction with cardiac troponin I, the protein was accordingly named cardiac TNNI3K. 7 Early in vitro work suggested that TNNI3K overexpression was protective, resulting in an inhibition of apoptosis and the reduction in MAPK phosphorylation. In addition, mice treated with intramyocardial injections of TNNI3K-overexpressing P19CL6 cells developed smaller infarcts sizes after chronic coronary artery occlusion. 8 These early data suggested that TNNI3K had a protective role after injury.
A cardioprotective role for TNNI3K was challenged by work from our group, which showed that both normal expression and TNNI3K overexpression had a deleterious effect on cardiac function. This was demonstrated through studies of inbred and congenic mouse strains, which revealed significant heterogeneity in their baseline expression of TNNI3K. Significantly, some inbred strains effectively harbor a natural, null (loss-of-function) allele, displaying 100-fold less TNNI3K expression than most other strains. Mouse strains harboring the normally, high TNNI3K expression allele showed an accelerated and exacerbated disease course in 2 different models of cardiomyopathy, whereas strains harboring the natural null allele displayed milder disease. Importantly, transgenic TNNI3K overexpression also resulted in marked worsening of mortality, cardiac function, and left ventricular remodeling. 9 The current work presented by Vagnozzi et al 3 supports the hypothesis that TNNI3K has a deleterious effect on the mammalian cardiac response to injury and that the inhibition of this kinase has a protective role.
Apart from its role in ischemic injury, recent work has suggested that TNNI3K has other roles in cardiac structure and function. Cardiac hypertrophy induced by pressure overload 10 resulted in increased expression of TNNI3K. Moreover, genetic overexpression of TNNI3K resulted in spontaneous hypertrophy both in vivo and in vitro. However, in the current article, the genetic deletion of TNNI3K did not result in a significant change in hypertrophy in the basal state or after ischemic injury. 3 Although recent work has suggested that TNNI3K has a limited role in the regulation of sarcomeric proteins, recent work by both our group and other laboratories has suggested that this is not the case. Phosphorylation of cardiac troponin I is known to affect myofilament sensitivity and cardiac inotropy. 6 Overexpression of TNNI3K has been shown to enhance phosphorylation at serine 43 and threonine 143 and was associated with increased isolated myocyte contractility. 6 In addition, overexpression of TNNI3K is associated with increased sarcomere length and titin isoform switching, which were independent of p38 phosphorylation. 5 Both of these alterations would potentially have significant effects on cardiac systolic and diastolic function. Recent evidence suggests that TNNI3K may be involved in cardiac electric conduction, particularly in the generation of normal atrioventricular conduction. 11 Taken together, the data suggest that TNNI3K seems to have a vital role in several important aspects of cardiac function, ventricular remodeling, contractile function, and response to injury (Figure) .
Recent genetics studies support the assertion that TNNI3K may have more diverse functions. In the mouse, TNNI3K has been identified as a potentially important gene in host response to viral cardiomyopathies caused by Coxsackie B virus. 12 In this context, the murine allele with normally, high TNNI3K expression seems to confer a protective role in viral cardiomyopathy. Apart from response to cardiac injury, recent human genetic studies have suggested an intriguing role for TNNI3K in the development of obesity. 13, 14 Although this association seems to be present in diverse populations, the mechanistic details of this association are still unclear and may instead be related to a gene mapping near TNNI3K. Intriguingly, a naturally occurring read-through transcript is found for TNNI3K and its adjacent gene, fucose-1-phosphate guanylyltransferase, suggesting the possibility that phenotypes associated with SNPs (single nucleotide polymorphisms) in the vicinity of the TNNI3K gene may instead be related to this unusual fusion protein. However, the recent findings from Vagnozzi et al 3 of effect of TNNI3K on mitochondrial function may indeed suggest a direct role for TNNI3K in human obesity. Additional studies of TNNI3K function may yield insights into the nature of the association among this gene, metabolic function, and body morphology.
The article published by Vagnozzi et al 3 suggests that TNNI3K may play a critical role in the development of ischemia-reperfusion injury and provides proof-of-principle that TNNI3K blockers may have a clinical application. However, the clinical application of TNNI3K may present some challenges. To date, several candidate approaches that seem to have significant efficacy in animal models have yielded largely disappointing results in treating reperfusion injury in humans. 15 This may, in part, be explained by the timing of when these therapies are administered after the onset of myocardial infarction, effect of preexisting medications, and genetic heterogeneity. 1 Heterogeneity of basal TNNI3K function in humans, which recent genetic studies suggest is significant, may present challenges to applying to this novel therapy for ? Figure. Function of troponin I-interacting kinase (TNNI3K) in response to cardiac injury. After ischemia-reperfusion injury, TNNI3K induces p38 phosphorylation, either through direct phosphorylation on in an indirect manner. Activation of p38 results increased mitochondrial induced reactive oxygen species production and subsequent changes in infarction size and remodeling. The hypertrophic response, in response to pressure overload for example, seems to be independent of p38 activation. However, it is not known whether changes in oxidative stress or mitochondrial dysfunction downstream of TNNI3K is involved in the development of cardiac hypertrophy.
ischemia-reperfusion injury. However, because our understanding of the relevance and function of TNNI3K grows, the novel drugs to block TNNI3K function may have a broader application in mitigating other forms of cardiac injury and effect metabolic function.
